New pill HRS-4508 targets tough lung cancers

NCT ID NCT07003321

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called HRS-4508 in people with advanced non-small cell lung cancer that has not responded to or cannot tolerate standard treatments. About 120 participants will take the drug as a tablet. Researchers will check how safe it is and whether it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HRS-4508 tablet
What this could lead to: If successful, this could provide a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong: This is an early Phase 2 trial with only 120 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200433, China

Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.